SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2023.
“Thanks to the depth and breadth of our team’s virology drug development expertise, we were thrilled to nominate the first development candidate from our expanded virology pipeline, 5366, during the first quarter,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “With 5366 targeting high-recurrence genital herpes expected to enter the clinic in the first half of 2024 and nomination of a second pipeline candidate anticipated later this year, we look forward to advancing these new programs that are designed to address significant unmet medical needs with the potential for shorter paths to reaching key inflection points and clinical proof of concept.”
“With respect to our core inhibitors, we reported promising additional clinical data for 4334 and made the strategic decision to evaluate partnering options for our core inhibitor portfolio,” continued Mr. Okazaki. “We believe partnering the core inhibitors will enable opportunities for further clinical development aimed at achieving a functional cure for HBV, including through combination approaches. It also allows our teams to focus on accelerating 5366 and other compounds in our expanded virology portfolio, which offer us greater potential to have a near-term impact for patients and stockholders.”
First Quarter 2023 and Recent Highlights
Anticipated Milestones and Events
Upcoming Conferences
First Quarter 2023 Financial Results
About Assembly Biosciences
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor and Corporate:
Shannon Ryan
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Sam Brown Inc.
Hannah Hurdle
(805) 338-4752
This email address is being protected from spambots. You need JavaScript enabled to view it.
| ASSEMBLY BIOSCIENCES, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (In thousands except for share amounts and par value) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 43,482 | $ | 52,418 | ||||
| Marketable securities | 29,534 | 39,192 | ||||||
| Accounts receivable from collaboration | 717 | 944 | ||||||
| Prepaid expenses and other current assets | 6,011 | 4,413 | ||||||
| Total current assets | 79,744 | 96,967 | ||||||
| Property and equipment, net | 619 | 743 | ||||||
| Operating lease right-of-use (ROU) assets | 2,419 | 3,195 | ||||||
| Other assets | 334 | 889 | ||||||
| Total assets | $ | 83,116 | $ | 101,794 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,224 | $ | 2,493 | ||||
| Accrued research and development expenses | 3,046 | 3,122 | ||||||
| Other accrued expenses | 3,154 | 7,317 | ||||||
| Operating lease liabilities - short-term | 2,546 | 3,364 | ||||||
| Total current liabilities | 9,970 | 16,296 | ||||||
| Deferred revenue | 2,733 | 2,733 | ||||||
| Operating lease liabilities - long-term | 80 | 101 | ||||||
| Total liabilities | 12,783 | 19,130 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding | — | — | ||||||
| Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 52,015,268 and 48,894,973 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 52 | 49 | ||||||
| Additional paid-in capital | 814,264 | 807,938 | ||||||
| Accumulated other comprehensive loss | (513 | ) | (803 | ) | ||||
| Accumulated deficit | (743,470 | ) | (724,560 | ) | ||||
| Total stockholders' equity | 70,333 | 82,624 | ||||||
| Total liabilities and stockholders' equity | $ | 83,116 | $ | 101,794 | ||||
| ASSEMBLY BIOSCIENCES, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||
| (In thousands except for share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 14,547 | $ | 17,205 | ||||
| General and administrative | 5,012 | 5,957 | ||||||
| Total operating expenses | 19,559 | 23,162 | ||||||
| Loss from operations | (19,559 | ) | (23,162 | ) | ||||
| Other income | ||||||||
| Interest and other income, net | 609 | 71 | ||||||
| Total other income | 609 | 71 | ||||||
| Net loss | $ | (18,950 | ) | $ | (23,091 | ) | ||
| Other comprehensive loss | ||||||||
| Unrealized gain (loss) on marketable securities | 290 | (489 | ) | |||||
| Comprehensive loss | $ | (18,660 | ) | $ | (23,580 | ) | ||
| Net loss per share, basic and diluted | $ | (0.37 | ) | $ | (0.48 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 51,012,450 | 48,123,930 | ||||||
| Last Trade: | US$10.80 |
| Daily Change: | -0.24 -2.17 |
| Daily Volume: | 7,516 |
| Market Cap: | US$68.690M |
February 26, 2025 December 19, 2024 November 07, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
